OBJECTIVES: To evaluate the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) in clear cell renal cell carcinoma (CCRCC) and to investigate its prognostic significance. ERK1/2 activation had been reported in RCC, but little is known about its prognostic significance. METHODS: We immunohistochemically analyzed phosphorylated ERK1/2 (pERK) expression using tissue microarrays in 328 CCRCC specimens. The percentage of tumor cells showing positive staining was evaluated and classified into 4 categories: 0, 0%; 1+, 1%-10%; 2+, 11%-50%; and 3+, > 50%. For statistical analysis, the cases were subdivided into pERK-low (0 and 1+) and pERK-high (2+ and 3+) expression. RESULTS: Our study showed significantly greater expression of pERK in CCRCC than in non-neoplastic renal parenchyma. pERK-high expression was significantly associated with a low pT category (P = .046). The survival analysis showed a significant association between pERK-high expression and better progression-free survival (P = .014). Furthermore, the prognostic significance of pERK expression was quite different between small CCRCC (size < or = 7 cm) and large CCRCC (size > 7 cm) lesions. In small CCRCC, pERK-high expression correlated significantly with better cancer-specific survival (P = .018) and better progression-free survival (P < .001). However, no correlation was found between pERK expression and survival in large CCRCC. CONCLUSIONS: High expression of pERK in CCRCC was associated with a low pT category and showed a longer progression-free survival, especially in small CCRCC. Although the biologic mechanism of the ERK pathway in CCRCC remains unknown, the results of this study suggest that pERK expression is a positive prognosticator for survival in those with small CCRCC.
OBJECTIVES: To evaluate the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) in clear cell renal cell carcinoma (CCRCC) and to investigate its prognostic significance. ERK1/2 activation had been reported in RCC, but little is known about its prognostic significance. METHODS: We immunohistochemically analyzed phosphorylated ERK1/2 (pERK) expression using tissue microarrays in 328 CCRCC specimens. The percentage of tumor cells showing positive staining was evaluated and classified into 4 categories: 0, 0%; 1+, 1%-10%; 2+, 11%-50%; and 3+, > 50%. For statistical analysis, the cases were subdivided into pERK-low (0 and 1+) and pERK-high (2+ and 3+) expression. RESULTS: Our study showed significantly greater expression of pERK in CCRCC than in non-neoplastic renal parenchyma. pERK-high expression was significantly associated with a low pT category (P = .046). The survival analysis showed a significant association between pERK-high expression and better progression-free survival (P = .014). Furthermore, the prognostic significance of pERK expression was quite different between small CCRCC (size < or = 7 cm) and large CCRCC (size > 7 cm) lesions. In small CCRCC, pERK-high expression correlated significantly with better cancer-specific survival (P = .018) and better progression-free survival (P < .001). However, no correlation was found between pERK expression and survival in large CCRCC. CONCLUSIONS: High expression of pERK in CCRCC was associated with a low pT category and showed a longer progression-free survival, especially in small CCRCC. Although the biologic mechanism of the ERK pathway in CCRCC remains unknown, the results of this study suggest that pERK expression is a positive prognosticator for survival in those with small CCRCC.
Authors: Francisco A Aguilar-Alonso; José D Solano; Chabetty Y Vargas-Olvera; Ignacio Pacheco-Bernal; Telma O Pariente-Pérez; María Elena Ibarra-Rubio Journal: Mol Cell Biochem Date: 2015-02-28 Impact factor: 3.396
Authors: Guoqiang Li; Weimin Ci; Subhradip Karmakar; Ke Chen; Ruby Dhar; Zhixiang Fan; Zhongqiang Guo; Jing Zhang; Yuwen Ke; Lu Wang; Min Zhuang; Shengdi Hu; Xuesong Li; Liqun Zhou; Xianghong Li; Matthew F Calabrese; Edmond R Watson; Sandip M Prasad; Carrie Rinker-Schaeffer; Scott E Eggener; Thomas Stricker; Yong Tian; Brenda A Schulman; Jiang Liu; Kevin P White Journal: Cancer Cell Date: 2014-03-20 Impact factor: 31.743
Authors: B K Nayak; D Feliers; S Sudarshan; W E Friedrichs; R T Day; D D New; J P Fitzgerald; A Eid; T Denapoli; D J Parekh; Y Gorin; K Block Journal: Oncogene Date: 2012-08-06 Impact factor: 9.867